Email updates

Keep up to date with the latest news and content from Journal of Cardiovascular MR and BioMed Central.

This article is part of the supplement: Abstracts of the 16th Annual SCMR Scientific Sessions

Open Access Open Badges Oral presentation

Interstitial expansion in pressure overload left ventricular hypertrophy

Thomas A Treibel1*, Steven K White12, Daniel Sado1, Filip Zemrak3, Sanjay M Banypersad1, Andrew Flett1, Mark Caulfield3, Anna S Herrey1, Steffen E Petersen3 and James Moon1

  • * Corresponding author: Thomas A Treibel

Author Affiliations

1 The Heart Hospital Imaging Centre, University College London, London, UK

2 The Hatter Cardiovascular Institute, University College London Hospitals NHS Trust, London, UK

3 Cardiovascular Biomedical Research Unit, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK

For all author emails, please log on.

Journal of Cardiovascular Magnetic Resonance 2013, 15(Suppl 1):O92  doi:10.1186/1532-429X-15-S1-O92

The electronic version of this article is the complete one and can be found online at:

Published:30 January 2013

© 2013 Treibel et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Diffuse myocardial fibrosis (DMF) is an important factor in cardiac disease, but until recently could only be accurately assessed with biopsy. We hypothesised that DMF measured by Equilibrium contrast CMR (EQ-CMR) is elevated in cardiac pressure overload (hypertension and aortic stenosis), that the degree of DMF will track the clinical severity of pressure overload and cardiac effects, and as such DMF may be a key biomarker in assessing the cardiac effects of pressure overload.


ECV measurement was by EQ-CMR. The T1 mapping sequence was ShMOLLI. The contrast agent was Gadoterate meglumine (Dotarem) at 0.1mmol/Kg (bolus) plus infusion at 15 minutes at 0.0011 mmol/kg/min. CMR was at 1.5T (Siemens Avanto):

ECV = (1-hematocrit)x (1/T1)myo ÷ (1/T1)blood.

ECV was measured in 43 patients with isolated, well-controlled hypertension (median age 56, range 21 to 78, 55% male), 28 patients with severe aortic stenosis (AS) undergoing aortic valve replacement (median age 70, range 60 to 84, 71% male), and 50 healthy volunteers (median age 47, range 28 to 69, 58% male).


ECV measurements were the lowest in the control group with significantly higher ECV values in hypertension and AS (0.261 versus 0.274 versus 0.296, p≤0.02; Figure 1).

thumbnailFigure 1. ECV measurements by EQ-CMR were the lowest in the control group with significantly higher ECV values in hypertension and aortic stenosis (0.261 versus 0.274 versus 0.296,p≤0.02).

The mass index increased from normal to hypertension to AS (66 g/m2 versus 85 g/m2 versus 101 g/m2, p<0.05; Figure 2), whereas the indexed left atrial area was only significantly higher in AS (11.0 and 11.6 cm2/m2 versus 13.2 cm2/m2, p<0.05); end-systolic and diastolic volumes were not significantly different among cohorts.

thumbnailFigure 2. The left ventricular mass index increased from normal to hypertension to aortic stenosis (66 g/m2 versus 85 g/m2 versus 101 g/m2, p<0.05).


The myocardial ECV increases with the degree of left ventricular pressure overload hypertrophy.


British Heart Foundation; National Institute for Health Research.